Skip to content

Effect of Monitoring Continuous Glucose Levels and Physical Activity Via Wearables on Cardiovascular Risk Factors

Effect of Monitoring Continuous Glucose Levels and Physical Activity Via Wearables on Cardiovascular Risk Factors After Cardiac Rehabilitation - A Randomised Controlled Trial: MITIGATE-RF

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05969665
Enrollment
100
Registered
2023-08-01
Start date
2024-02-07
Completion date
2025-08-31
Last updated
2024-08-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Risk Factors, Coronary Heart Disease, Physical Activity

Keywords

blood pressure, lipids, glucose level, smoking, weight, diet

Brief summary

The study aims to assess the effect of smart watches and continuous glucose measuring devices on cardiovascular risk factors.

Detailed description

Within a period of 4 months 100 patients will be recruited and randomised to the intervention or control arm (1:1) for a duration of 3 months. Randomisation will be stratified by age, sex, BMI, diabetes, blood pressure, and duration after finishing cardiac rehabilitation. Patients randomised to the intervention arm will be given a smart watch as well as a continuous blood glucose measurement device with detailed instructions. At baseline and at the end of the study questionnaires will be answered and anthropomorphic measurements attained. Blood samples will be drawn at baseline and after an intervention period of 3 months in all subjects. Additional data on sleep, temperature, heart rate (resting and exercise), breathing rate, activity and exercise, oxygen saturation and daily weight will be collected through the Fitbit web application programming interface (API).

Interventions

A smartwatch (Fitbit Inspire 2) with its respective app will be worn by the patients in the intervention group for 3 months.

DEVICEAbbott Freestyle Libre 3

A continuous glucose measuring device (Abbott Freestyle Libre 3) with its respective app will be worn by the patients in the intervention group for 3 months.

Sponsors

University Hospital, Basel, Switzerland
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Intervention model description

single-centre, randomized controlled, open-label trial

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Informed Consent signed by the subject * Completed outpatient cardiac rehabilitation * Diagnosis of coronary heart disease * Access to a smartphone for the duration of the study * 18 years or older on the date of consent

Exclusion criteria

* Diseases which limit physical activity including angina with incomplete revascularisation, arrhythmogenic cardiomyopathy, stroke with residual disease, and major orthopaedic disorders * Known or suspected non-compliance * Inability to follow the procedures of the investigation, e.g., due to language problems, psychological disorders, dementia, etc. of the subject * Diabetic patients receiving insulin therapy * Lack of proficiency with smart phone/watch * Current participation in any other clinical trial, which may confound the results of this trial. * NYHA (New York Heart Association) class III or IV congestive heart failure * Pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Change in cardiovascular risk factor score blood pressureat baseline and after 3 monthFor the risk factor blood pressure 0 to 2 points will be awarded. 2 points will be rewarded if the patient reaches the goals according to ESC (European Society of Cardiology) -Guidelines where applicable, 1 point if the patient reaches the goal partially and 0 if the patient does not reach the goal. Goals according to ESC Guidelines: Systolic 120-130 mmHg (18-69y.) Systolic \< 140 mmHg (70y.) Diastolic \< 80 mmHg (all ages) Points according to goals: 2 = age related SBP (systolic blood pressure) & DBP (diastolic blood pressure) goals 1 = \< 140 mmHg, \> 130 mmHg 18-69yr. or \< 140 mmHg and \> 90 mmHg DBP \>70yr 0 = SBP \> 140 mmHg
Change in cardiovascular risk factor score LDLat baseline and after 3 monthFor the risk factor LDL 0 to 2 points will be awarded. 2 points will be rewarded if the patient reaches the goals according to ESC-Guidelines where applicable, 1 point if the patient reaches the goal partially and 0 if the patient does not reach the goal. Goals according to ESC Guidelines: LDL \<1.4 mmol/l and 50% reduction from baseline Points according to goals: 2 = \< 1.4 mmol/l 1 = \< 1.8 mmol/l 0 = \> 1.8 mmol/l
Change in cardiovascular risk factor score HbA1cat baseline and after 3 monthFor the risk factor HbA1c 0 to 2 points will be awarded. 2 points will be rewarded if the patient reaches the goals according to ESC-Guidelines where applicable, 1 point if the patient reaches the goal partially and 0 if the patient does not reach the goal. Goals according to ESC Guidelines: DM (diabetes mellitus) HbA1c \< 7.0% or \< 6.5% in recent diagnosis No DM \< 5.7% (cut-off prediabetes) Points according to goals: 2 = \< 5.7 % 1 = 5.7 - 6.5 % 0 = \> 6.5 %
Change in cardiovascular risk factor score BMIat baseline and after 3 monthFor the risk factor BMI 0 to 2 points will be awarded. 2 points will be rewarded if the patient reaches the goals according to ESC-Guidelines where applicable, 1 point if the patient reaches the goal partially and 0 if the patient does not reach the goal. Goals according to ESC Guidelines: BMI 20-25 kg/m2 AC (Abdominal circumference) \< 102 (men) \< 88 (women) WHR (waist to hip ratio) 0.75-0.9 men & 0.70-0.85 women Points according to goals: 2 = BMI and AC in range 1 = only BMI or AC in range 0 = nothing in range
Change in cardiovascular risk factor score physical activityat baseline and after 3 monthFor the risk factor physical activity 0 to 2 points will be awarded. 2 points will be rewarded if the patient reaches the goals according to ESC-Guidelines where applicable, 1 point if the patient reaches the goal partially and 0 if the patient does not reach the goal. Goals according to ESC Guidelines: \> 150min/week moderate PA (mPA), better 300min/week (self-reported) or \> 75min/week vigorous PA (vPA), better 150min/week (self-reported) Points according to goals: 2 = \> 300 min. mPA or \> 150 min. vPA 1 = \> 150 min. mPA or \> 75 min. vPA 0 = \< 150 min. mPA or \< 75 min. vPA Or mix or mPA and vPA respectively
Change in cardiovascular risk factor score nutritionat baseline and after 3 monthFor the risk factor nutrition 0 to 2 points will be awarded. 2 points will be rewarded if the patient reaches the goals according to ESC-Guidelines where applicable, 1 point if the patient reaches the goal partially and 0 if the patient does not reach the goal. Goals according to ESC Guidelines: ≥ 5 portions fruit/vegetables a day Unsalted nuts ≥ 3x/week Reduction in saturated fats Points according to goals: 2 = 5/day OR 4/day + nuts 3x/week + reduction in saturated fats 1 = 4/day OR 3/day + nuts 3x/week + reduction in saturated fats 0 = \< 4/day
Change in cardiovascular risk factor score smokingat baseline and after 3 monthFor the risk factor smoking 0 or 3 points will be awarded. Points according to goals: Smoking (yes/no) 3 = no 0 = yes

Countries

Switzerland

Contacts

Primary ContactJan Gerrit van der Stouwe, Dr. med.
jangerrit.vanderstouwe@usb.ch+41 61 265 44 44
Backup ContactPatrick Badertscher, Dr. med.
patrick.badertscher@usb.ch+41 61 265 52 14

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026